With the recent Alzheimer's Association International Conference suggesting a new era of hope for sufferers of the illness, drug trials have shown some enlightening discoveries.
But Alzheimer's isn’t the only neurodegenerative disease and drug possibilities in this market continue to expand. Visiongain reveal that the market value for the Neurodegenerative market was worth over $16 billion in 2006, with revenues growth anticipated to exceed $18 billion in 2007. But what will it be in 2012? This report will tell you.
This report provides comprehensive information on the neurodegenerative diseases; Parkinson's Disease, Alzheimer’s Disease, Multiple Sclerosis and Neuropathic pain. The report also covers rare genetic disorders-Huntington disease, Amyotrophic Lateral Sclerosis a niche market disease classification and also Prion diseases.
The report tackles how the significant rise in the growing population age “Baby Boom” generation, paralleled with longevity across the globe will be a major catalyst for the pharmaceutical/health care sector revenue growth in the long-term. It also analyses periods of sustained revenue growth, during 2007-2012, and how expectant patent expirations on some major blockbuster drugs with strong market shares will boost revenues in the generics market. The neurodegenerative report also sheds significant emphasis on the financial burden of the neurodegenerative diseases on national healthcares services.
Advancement in innovation in the global pharmaceutical and healthcare sector are expected to spiral global annual earnings for the major market leaders including Biogen Idec, Elan, Eli Lilly, Novartis and Pfizer.
The Visiongain Neurodegenerative Market report looks at a broad spectrum of therapies during disease treatment, including;
• Biogen Idec and Elan’s Tysabri for remitting relapsing Multiple Sclerosis
• GW’s Cannabinoid product Sativex for Multiple Sclerosis
• Eli Lilly’s Cymbalta and Pfizer’s Lyrica indication for Neuropathic pain relief.
The report answers questions such as:
- In the next 5 years what will be the successful drugs
- Is stem cell research the answer for these diseases?
- Which of the current therapies show the greatest revenue generation potential?
- How will new drug development technologies impact on neuro disorders?
Visiongain’s, Global Neurodegenerative Market Reports provides a rich insight on current research underway globally by leading industries in pharmaceutical/ Biotech sector coupled with ,unbiased market forecast, affected by views of Healthcare regulatory authorities.
Visiongain’s Global Neurodegenerative Markets provides solutions to questions search as;
• Which regions have the highest prevalence of these diseases today and by 2020?
• What market share is accounted for by individual diseases in the neurodegenerative market?
• What is the global cost of neurodegenerative diseases and the significant market shares?
• How much the 2007 neurodegenerative market is to be valued at and what it will be worth by 2012?
• Which are the market leaders in this class of therapy?
• What are the current approved therapies in the market and are they more effective than present treatments?
• Which first line drugs will be coming off patent by 2012 and what are implications to the market?
• Which drugs have been withdrawn from the neurodegenerative market?
• Which molecules are currently in the pipelines that are deemed to answer unmet therapeutic needs in the future?
Why You Must Buy This Report:
Visiongain’s, Global Neurodegenerative Market Report, provides up-to-date analysis of present and future market illustrated by substantial number of charts and figures. It also discusses strategies employed by key players in the industries. This is a must buy report, as it will provide you with useful information on business opportunities in the big and niche markets.
The revenue forecasts generated in this report are exclusive to this report and are determined by the market, its future prospects in terms of patent protection, generic competition, life-cycle management, licensing agreements and market activity. With in-depth primary and secondary research, the forecasts run up to 2012. It will provide you with information on the dynamics of the Neurodegenerative Disease Market, and its operation until that time.
More key questions that this report answers:
• What is the potential population treatment in the major global markets up to 2012?
• Which are the main therapeutic agents dictating the pace of the market?
• What companies are the major drivers in the market?
• What is the present market activity and are the therapies effective?
• What is the envisaged Market activity in 2012?
• How will the growing population size affect the market in 2012 (Is big pharma up to the challenge?)
• How condensed is the Neurodegenerative drug pipeline?
• What is big pharma doing to narrow unmet therapeutic demands?